Annals of Clinical and Translational Neurology (Mar 2024)

Lower limb muscle MRI fat fraction is a responsive outcome measure in CMT X1, 1B and 2A

  • Carolynne M. Doherty,
  • Jasper M. Morrow,
  • Riccardo Zuccarino,
  • Paige Howard,
  • Stephen Wastling,
  • Menelaos Pipis,
  • Nick Zafeiropoulos,
  • Katherine J. Stephens,
  • Tiffany Grider,
  • Shawna M. E. Feely,
  • Peggy Nopoulous,
  • Mariola Skorupinska,
  • Evelin Milev,
  • Emma Nicolaisen,
  • Magdalena Dudzeic,
  • Amy McDowell,
  • Nuran Dilek,
  • Francesco Muntoni,
  • Alexander M. Rossor,
  • Sachit Shah,
  • Matilde Laura,
  • Tarek A. Yousry,
  • Daniel Thedens,
  • John Thornton,
  • Michael E. Shy,
  • Mary M. Reilly

DOI
https://doi.org/10.1002/acn3.51979
Journal volume & issue
Vol. 11, no. 3
pp. 607 – 617

Abstract

Read online

Abstract Objective With potential therapies for many forms of Charcot‐Marie‐Tooth disease (CMT), responsive outcome measures are urgently needed for clinical trials. Quantitative lower limb MRI demonstrated progressive calf intramuscular fat accumulation in the commonest form, CMT1A with large responsiveness. In this study, we evaluated the responsiveness and validity in the three other common forms, due to variants in GJB1 (CMTX1), MPZ (CMT1B) and MFN2 (CMT2A). Methods 22 CMTX1, 21 CMT1B and 21 CMT2A patients and matched controls were assessed at a 1‐year interval. Intramuscular fat fraction (FF) was evaluated using three‐point Dixon MRI at thigh and calf level along with clinical measures including CMT examination score, clinical strength assessment, CMT‐HI and plasma neurofilament light chain. Results All patient groups had elevated muscle fat fraction at thigh and calf levels, with highest thigh FF and atrophy in CMT2A. There was moderate correlation between calf muscle FF and clinical measures (CMTESv2 rho = 0.405; p = 0.001, ankle MRC strength rho = −0.481; p < 0.001). Significant annualised progression in calf muscle FF was seen in all patient groups (CMTX1 2.0 ± 2.0%, p < 0.001, CMT1B 1.6 ± 2.1% p = 0.004 and CMT2A 1.6 ± 2.1% p = 0.002). Greatest increase was seen in patients with 10–70% FF at baseline (calf 2.7 ± 2.3%, p < 0.0001 and thigh 1.7 ± 2.1%, p = 0.01). Interpretation Our results confirm that calf muscle FF is highly responsive over 12 months in three additional common forms of CMT which together with CMT1A account for 90% of genetically confirmed cases. Calf muscle MRI FF should be a valuable outcome measure in upcoming CMT clinical trials.